Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1701724

registered interest
date	17/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Incontinence: Products
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make a comparative assessment of the cost to the NHS of different kinds of absorbent continence products based on the (a) item price and (b) patient experience and outcome including (i) whole system cost, (ii) laundry cost and (iii) environmental impact.
tabling member constituency	South West Bedfordshire
tabling member printed	Andrew Selous
uin	22265
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Government is working with NHS England and partner organisations across the health system to develop a standardised methodology, to assess the full value of medical technologies. This initiative underlines our commitment in the Medtech Strategy, published in February 2023, ensuring the right product, in the right place, at the right price. The methodology will seek to look beyond upfront cost to consider patient outcomes, whole system costs, supply resilience, and the environmental impact when procurement decisions are being made.</p><p> </p><p>The methodology will provide a consistent approach to assessing value, and will be implemented at both the national and local level. This approach aims to ensure that procurement decisions support both short-term efficiencies and long-term benefits, drawing out the value to patients and the healthcare system. The Government appreciates contributions from the industry and procurement communities, and will invite stakeholders to provide feedback on the initial proposal in due course.</p><p> </p><p>In terms of implementation, we will look to align and integrate this initiative with NHS England’s Central Commercial Function's ongoing work under their strategic framework, which aims to create commercial playbooks for standardising practices and processes across the National Health Service.</p><p> </p><p>Regarding the specific point raised around absorbent continence products, the Disposable Continence tender is due to be issued to the market later this year. To ensure that the NHS’s requirements are considered during the procurement process, NHS Supply Chain is undertaking significant engagement across the health and social care system. This includes customers in the acute and wider community setting, suppliers, trade associations, professional bodies, and end user reference groups, to understand their requirements from a commercial, value, sustainability, and supply resilience perspective.</p><p> </p><p>NHS Supply Chain is currently working with suppliers of disposable continence products to understand the value-based procurement and sustainability offerings on the purchase of continence products. NHS Supply Chain has identified a trust who are committed in supporting us in understanding this value in the form of a pilot study, and potential case study. More information can be provided once these studies have been finalised and confirmed.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 21932 21933 question first answered 22/04/2024 11:00:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1453 label Biography information for Andrew Selous

1701733

registered interest
date	17/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia: Northern Ireland
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether Northern Ireland will receive funding through the Dame Barbara Windsor Dementia mission; and what her planned timetable for delivery of the mission is.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	22258
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>Spending and delivery plans for the Dame Barbara Windsor Dementia Mission are currently in development. The Dementia Mission Co-Chairs Hilary Evans and Professor Nadeem Sarwar have, and continue to, engage extensively across the sector to understand and develop the missions’ key aims, ensuring it addresses the challenges the sector faces and that patient voices are heard. This has informed the missions focus on three key pillars: biomarkers and experimental medicine; clinical trials infrastructure and innovation; and end-to-end implementation.</p><p>In March 2024, the Government hosted a roundtable and reception where charities, academics, investors, business leaders, and people with lived experience came together to further accelerate efforts to tackle this devastating illness, and to thank all those involved in supporting dementia research, including charities across the United Kingdom. This event made a series announcements, including: awarding a share of the £6 million of funding to 10 projects through Innovate UK’s Small Business Research Initiative (SBRI) dementia biomarker tools competition; the appointment of Scott Mitchell as the People’s Champion for the Dementia Mission; the appointment of Dr Ruth McKernan CBE as Chair of the Scientific Advisory Board for the Neurodegeneration Initiative, which will be a public-private partnership delivering the mission's objectives around biomarkers, boosting the number and speed of clinical trials in dementia and neurodegeneration, and working with regulatory bodies around the implementation of new treatments; and the appointment of the Medicines Discovery Catapult as the delivery partner for the establishment of the Neurodegeneration Initiative. The Dame Barbara Windsor Dementia Mission continues to develop its deliverables, and will announce further plans for their delivery in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 10:51:18 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1409 label Biography information for Mr Gregory Campbell

1701863

registered interest
date	17/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what funding has her Department allocated to provide recovery spaces for families of cancer treatment patients.
tabling member constituency	Wirral South
tabling member printed	Alison McGovern
uin	22297
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer treatment, which encompasses recovery spaces. Additionally, and as outlined in the 2024/25 NHS England Planning Guidance, NHS England are providing over £266 million in cancer service development funding to Cancer Alliances, to support delivery of the operational priorities for cancer.</p><p>The Department and NHS England meet regularly to discuss a wide range of issues regarding cancer. The Department's ministers and officials also frequently meet with key stakeholders within the cancer community, including discussions on support for patients and their families. As stated in the NHS Long Term Plan for Cancer, where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan and health and wellbeing information, and support. NHS England provides personalised cancer care and support plans, to support both patients and their families at all stages of their cancer journey. This is being delivered in line with the NHS Comprehensive Model for Personalised Care, empowering people to manage their care and the impact of their cancer, and maximise the potential of digital and community-based support. NHS England estimates that approximately 80% of cancer multidisciplinary teams are now offering Personalised Care and Support Planning, ensuring physical, practical, emotional, and social needs are identified and addressed at all stages of the cancer pathway. Additionally, Personalised Stratified Follow Up pathways, which adapt care to the needs of individual patients after cancer treatment, are being rolled out by cancer multi-disciplinary teams, and are required for at least eight cancer types by 2023/24.</p><p>General practice surgeries also conduct cancer care reviews at regular intervals after cancer diagnosis, to offer support with any needs patients may have. This includes providing access to other specialist-led services who work alongside patients’ medical teams, to support patients and their families, such as counsellors, rehabilitation specialists, or social prescribers, who can connect you to community groups or services for more support. This is part of NHS England’s drive to universal personalised care that will see at least 2.5 million people benefiting from personalised care by 2023/24.</p><p>NHS England and the integrated care boards are responsible for commissioning and ensuring the healthcare needs of local communities in England are met, including for cancer patients. NHS England provide access to a personal health budget, which is an amount of NHS money that is allocated to support the health and wellbeing needs of a patient if eligible. More information is available at the following link:</p><p><a href="https://www.nhs.uk/nhs-services/help-with-health-costs/what-is-a-personal-health-budget/" target="_blank">https://www.nhs.uk/nhs-services/help-with-health-costs/what-is-a-personal-health-budget/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22298 question first answered 22/04/2024 11:02:18 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4083 label Biography information for Alison McGovern

1701890

registered interest
date	17/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions her Department has had with cancer treatment support groups on the use of direct funds to support patients and their families.
tabling member constituency	Wirral South
tabling member printed	Alison McGovern
uin	22298
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer treatment, which encompasses recovery spaces. Additionally, and as outlined in the 2024/25 NHS England Planning Guidance, NHS England are providing over £266 million in cancer service development funding to Cancer Alliances, to support delivery of the operational priorities for cancer.</p><p>The Department and NHS England meet regularly to discuss a wide range of issues regarding cancer. The Department's ministers and officials also frequently meet with key stakeholders within the cancer community, including discussions on support for patients and their families. As stated in the NHS Long Term Plan for Cancer, where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan and health and wellbeing information, and support. NHS England provides personalised cancer care and support plans, to support both patients and their families at all stages of their cancer journey. This is being delivered in line with the NHS Comprehensive Model for Personalised Care, empowering people to manage their care and the impact of their cancer, and maximise the potential of digital and community-based support. NHS England estimates that approximately 80% of cancer multidisciplinary teams are now offering Personalised Care and Support Planning, ensuring physical, practical, emotional, and social needs are identified and addressed at all stages of the cancer pathway. Additionally, Personalised Stratified Follow Up pathways, which adapt care to the needs of individual patients after cancer treatment, are being rolled out by cancer multi-disciplinary teams, and are required for at least eight cancer types by 2023/24.</p><p>General practice surgeries also conduct cancer care reviews at regular intervals after cancer diagnosis, to offer support with any needs patients may have. This includes providing access to other specialist-led services who work alongside patients’ medical teams, to support patients and their families, such as counsellors, rehabilitation specialists, or social prescribers, who can connect you to community groups or services for more support. This is part of NHS England’s drive to universal personalised care that will see at least 2.5 million people benefiting from personalised care by 2023/24.</p><p>NHS England and the integrated care boards are responsible for commissioning and ensuring the healthcare needs of local communities in England are met, including for cancer patients. NHS England provide access to a personal health budget, which is an amount of NHS money that is allocated to support the health and wellbeing needs of a patient if eligible. More information is available at the following link:</p><p><a href="https://www.nhs.uk/nhs-services/help-with-health-costs/what-is-a-personal-health-budget/" target="_blank">https://www.nhs.uk/nhs-services/help-with-health-costs/what-is-a-personal-health-budget/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22297 question first answered 22/04/2024 11:02:18 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4083 label Biography information for Alison McGovern

1701915

registered interest
date	17/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Life Sciences: Artificial Intelligence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made on the £100 million AI Life Sciences Accelerator Mission.
tabling member constituency	Hove
tabling member printed	Peter Kyle
uin	22347
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Prime Minister announced a new artificial intelligence (AI) in healthcare fund, backed by £100 million, at the AI Safety Summit. The Department for Science, Innovation and Technology is responsible for this fund, and the Department of Health and Social Care is working closely with them to identify areas where rapid deployment of AI could create transformational breakthroughs in healthcare. We are particularly focused on innovations in Life Sciences, which could accelerate our fight against devastating conditions like cancer and chronic mental ill-health, aiming to diagnose these conditions earlier and improve treatments. The Department for Science, Innovation and Technology will provide an update on our progress later in Spring.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 10:56:22 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4505 label Biography information for Peter Kyle

1701263

registered interest
date	16/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Semaglutide: Health Hazards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to increase the public's awareness of the side effects that can arise from taking weight loss drugs such as Ozempic.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	21989
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) plays a pivotal role in ensuring the safety, efficacy, and quality of medicines and healthcare products available to patients in the United Kingdom. Patient safety remains the MHRA’s highest priority, and they take every opportunity to encourage reporting of any safety concerns to the Yellow Card scheme, which helps to improve the safe use of medicines and medical devices for everyone.</p><p>New medicines including, Mounjaro and Wegovy, are intensively monitored to ensure that any new safety concerns are identified promptly. The Commission on Human Medicines and the MHRA encourages the reporting of all suspected reactions to newer drugs and vaccines, which are denoted by an inverted Black Triangle symbol. This symbol appears next to the name of a relevant product in drug safety updates, the British National Formulary and the Nurse Prescribers’ Formulary, the monthly index of medical specialities, the electronic medicines compendium, and advertising material. Patient information leaflets accompanying licensed medicines in the UK must include a description of the adverse reactions which may occur in normal use of the medicinal product, as well as information on how to report them. All adverse reactions must be reflected in the leaflet, in language that the patient will understand.</p><p>The MHRA has received a small number of reports of falsified and unlicenced medicines being sold illegally online as a treatment for weight loss. The agency has issued public health messaging warning of the dangers of buying such medicines from illegal trading sources online.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 11:07:07 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4131 label Biography information for Jim Shannon

1701288

registered interest
date	16/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Cancer: Public Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has made a recent assessment of the effectiveness of the help us, help you campaign.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	21912
answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>No recent assessment has been made. In 2020 NHS England launched the Help Us, Help You (HUHY) campaigns, a major public information campaign to persuade the public to seek urgent care and treatment when they needed it. The HUHY campaign strategy is designed to address the underlying barriers to cancer diagnosis, including multifaceted fears and a lack of body vigilance, along with the lack of knowledge of cancer symptoms, to encourage people to present earlier.</p><p>On 8 January 2024, NHS England relaunched the HUHY campaign for cancer, designed to increase earlier diagnosis of cancer by reducing barriers to seeking earlier help, as well as increasing body vigilance and knowledge of key red flag symptoms. This campaign addresses barriers to people coming forward with suspected signs of cancer in general, and is not specific to screening or cervical cancer.</p><p>We are seeing continued high levels of urgent cancer referrals, which suggests the HUHY campaigns continue to be effective. Over 12,000 urgent referrals were seen for suspected cancer per working day in February 2024, compared to approximately 9,000 in January 2020.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/04/2024 07:32:51 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1409 label Biography information for Mr Gregory Campbell

1701290

registered interest
date	16/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate she has made of the number and proportion of NHS providers that have adopted two stage shared decision-making across all admitted pathways.
tabling member constituency	Bristol South
tabling member printed	Karin Smyth
uin	22045
answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>In May 2023, NHS England published guidance setting out five core perioperative care requirements relating to the care of adult patients awaiting planned inpatient surgery. One of these requirements is that patients must be involved in shared decision making regarding admitted pathways. NHS England does not collect data on the number of National Health Service providers that have adopted two stage shared decision making across all admitted pathways. NHS England’s published guidance is available at the following link:</p><p><a href="https://www.england.nhs.uk/long-read/earlier-screening-risk-assessment-and-health-optimisation-in-perioperative-pathways/#2-five-core-requirements-for-providers" target="_blank">https://www.england.nhs.uk/long-read/earlier-screening-risk-assessment-and-health-optimisation-in-perioperative-pathways/#2-five-core-requirements-for-providers</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/04/2024 09:58:11 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4444 label Biography information for Karin Smyth

1701292

registered interest
date	16/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nurses: Training
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many training places for district nurses her Department plans to make available in September 2025.
tabling member constituency	Bristol South
tabling member printed	Karin Smyth
uin	22047
answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>The NHS Long Term Workforce, published on 30 June 2023, sets out an ambition to increase the number of district nursing training places to 842 in 2025.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/04/2024 07:34:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4444 label Biography information for Karin Smyth

1701367

registered interest
date	16/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Incontinence: Products
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking with NHS England to (a) promote the adoption of the principles of value-based procurement in the purchase and dispensing of absorbent continence products and (b) help ensure that those principles continue to be adopted in the context of short-term savings being pursued by NHS organisations.
tabling member constituency	South West Bedfordshire
tabling member printed	Andrew Selous
uin	21932
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Government is working with NHS England and partner organisations across the health system to develop a standardised methodology, to assess the full value of medical technologies. This initiative underlines our commitment in the Medtech Strategy, published in February 2023, ensuring the right product, in the right place, at the right price. The methodology will seek to look beyond upfront cost to consider patient outcomes, whole system costs, supply resilience, and the environmental impact when procurement decisions are being made.</p><p> </p><p>The methodology will provide a consistent approach to assessing value, and will be implemented at both the national and local level. This approach aims to ensure that procurement decisions support both short-term efficiencies and long-term benefits, drawing out the value to patients and the healthcare system. The Government appreciates contributions from the industry and procurement communities, and will invite stakeholders to provide feedback on the initial proposal in due course.</p><p> </p><p>In terms of implementation, we will look to align and integrate this initiative with NHS England’s Central Commercial Function's ongoing work under their strategic framework, which aims to create commercial playbooks for standardising practices and processes across the National Health Service.</p><p> </p><p>Regarding the specific point raised around absorbent continence products, the Disposable Continence tender is due to be issued to the market later this year. To ensure that the NHS’s requirements are considered during the procurement process, NHS Supply Chain is undertaking significant engagement across the health and social care system. This includes customers in the acute and wider community setting, suppliers, trade associations, professional bodies, and end user reference groups, to understand their requirements from a commercial, value, sustainability, and supply resilience perspective.</p><p> </p><p>NHS Supply Chain is currently working with suppliers of disposable continence products to understand the value-based procurement and sustainability offerings on the purchase of continence products. NHS Supply Chain has identified a trust who are committed in supporting us in understanding this value in the form of a pilot study, and potential case study. More information can be provided once these studies have been finalised and confirmed.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 21933 22265 question first answered 22/04/2024 11:00:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1453 label Biography information for Andrew Selous